Cardiovascular changes associated with infusion of hematopoietic cell grafts in oncohematological patients - Impact of cryopreservation with dimethylsulfoxide

Experimental Oncology

Volumn 31, Issue 2, 2009, Pages 121-122

  Horacek, J M ^a,b   Jebavy, L ^a,b   Jakl, M ^b   Zak, P ^a   Mericka, P ^a   Maly, J ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Blood pressure; Cryopreservation; Dimethylsulfoxide; Heart rate; Transplantation

Indexed keywords

DIMETHYL SULFOXIDE; CRYOPROTECTIVE AGENT;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CANCER PATIENT; CARDIOVASCULAR DISEASE; CRYOPRESERVATION; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HEART RATE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; BLOOD DISEASE; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; METHODOLOGY; MIDDLE AGED;

BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CRYOPRESERVATION; CRYOPROTECTIVE AGENTS; DIMETHYL SULFOXIDE; FEMALE; HEART RATE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED;

EID: 68849102645     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. David NA. The pharmacology of dimethyl sulfoxide. Annu Rev Pharmacol 1972; 12: 353-374
2. Santos NC, Figueira-Coelho J, Martins-Silva J, Saldanha C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol 2003; 65: 1035-1041 (Pubitemid 36349743)
3. Rowley SD. Hematopoietic stem cell cryopreservation: a review of current techniques. J Hematother 1992; 1: 233-250
4. Berz D, McCormack EM, Winer ES, et al. Cryopreservation of hematopoietic stem cells. Am J Hematol 2007; 82: 463-472
5. Watt SM, Austin E, Armitage S. Cryopreservation of hematopoietic stem/progenitor cells for therapeutic use. Methods Mol Biol 2007; 368: 237-259
6. Liseth K, Abrahamsen JF, Bjørsvik S, et al. The viability of cryopreserved PBPC depends on the DMSO concentration and the concentration of nucleated cells in the graft. Cytotherapy 2005; 7: 328-333 (Pubitemid 41535837)
7. Bakken AM. Cryopreserving human peripheral blood progenitor cells. Curr Stem Cell Res Ther 2006; 1: 47-54.
8. Stroncek DF, Fautsch SK, Lasky LC, et al. Adverse reactions in patients transfused with cryopreserved marrow. Transfusion 1991; 31: 521-526
9. Zambelli A, Poggi G, Da Prada G, et al. Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res 1998; 18: 4705-4708 (Pubitemid 29042047)
10. Donmez A, Tombuloglu M, Gungor A, et al. Clinical side effects during peripheral blood progenitor cell infusion. Transfus Apher Sci 2007; 36: 95-101. (Pubitemid 46341968)
11. Davis JM, Rowley SD, Braine HG, et al. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990; 75: 781-786
12. Keung YK, Lau S, Elkayam U, et al. Cardiac arrhythmia after infusion of cryopreserved stem cells. Bone Marrow Transplant 1994; 14: 363-367 (Pubitemid 24295226)
13. López-Jiménez J, Cerveró C, Muñoz A, et al. Cardiovascular toxicities related to the infusion of cryopreserved grafts: results of a controlled study. Bone Marrow Transplant 1994; 13: 789-793 (Pubitemid 24195797)
14. Syme R, Bewick M, Stewart D, et al. The role of depletion of dimethyl sulfoxide before autografting: on hematologic recovery, side effects, and toxicity. Biol Blood Marrow Transplant 2004; 10: 135-141 (Pubitemid 38145867)
15. Martino M, Morabito F, Messina G, et al. Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients. Haematologica 1996; 81: 59-61. (Pubitemid 28020258)